Endovascular Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Endovascular surgery encompasses a broad range of minimally invasive catheter-based procedures performed inside blood vessels under fluoroscopic and angiographic guidance, without the need for open surgical exposure of the diseased vessel. The defining feature is percutaneous or small-incision access—most commonly through the common femoral artery—combined with deployment of devices (stent-grafts, stents, balloons, catheters) navigated to the target vessel through guidewires and sheaths under real-time imaging. Endovascular aneurysm repair (EVAR) is the most prominent endovascular aortic procedure: a bifurcated stent-graft consisting of a nitinol or stainless steel metal frame covered with polyester or PTFE fabric is deployed through bilateral femoral access to exclude the abdominal aortic aneurysm from systemic blood pressure. EVAR now accounts for over 75% of elective AAA repairs in developed countries. Thoracic endovascular aortic repair (TEVAR) addresses thoracic aortic aneurysms and acute type B aortic dissections. Fenestrated EVAR (FEVAR) extends endovascular repair to juxtarenal and pararenal aneurysms using custom-manufactured grafts with fenestrations and branches for visceral artery preservation. Branched EVAR (BEVAR) treats thoracoabdominal aneurysms. Peripheral vascular stenting, angioplasty, carotid artery stenting, renal artery stenting, and mesenteric stenting are additional endovascular domains. All aortic endovascular repairs require lifelong imaging surveillance.

Infrarenal abdominal aortic aneurysm (AAA) of 5.5 cm or greater (men) or 5.0 cm or greater (women) with suitable anatomy is the primary EVAR indication. Juxtarenal AAA with inadequate infrarenal neck length requires FEVAR with custom-manufactured fenestrated grafts for renal and superior mesenteric artery preservation. Thoracoabdominal aortic aneurysms (TAAA) involving the visceral segment are addressed by BEVAR at specialized centers where OSR carries prohibitive risk. Thoracic aortic aneurysms of 5.5–6.0 cm are treated with TEVAR. Acute complicated type B aortic dissection (malperfusion of limb, renal, or mesenteric vessels; rupture; or refractory hypertension) is managed urgently with TEVAR to expand the true lumen and restore perfusion. Acute aortic syndromes including penetrating aortic ulcer and intramural hematoma with high-risk features are treated with TEVAR. Ruptured AAA can be treated with emergency EVAR when anatomy is suitable, identified by rapid CT angiography in hemodynamically stable or temporarily stabilized patients. Peripheral arterial occlusive disease of iliac, femoral, and tibial arteries is treated with angioplasty and stenting. Carotid artery stenting is indicated for high-risk-for-surgery patients with significant carotid stenosis.

Anatomic suitability assessment by CT angiography is the essential prerequisite for endovascular aortic repair. Standard EVAR requires: infrarenal neck length at least 15 mm, neck diameter 18–32 mm, neck angulation below 60 degrees, absence of excessive neck thrombus or calcification, iliac access vessels at least 7 mm in diameter without severe tortuosity, and adequate common iliac artery landing zones. Patients failing standard EVAR anatomy may qualify for FEVAR (juxtarenal neck) if the mesenteric and renal vessels are suitable for fenestration. FEVAR requires a custom device manufacturing lead time of 3–6 weeks, limiting its use to elective cases. Emergency EVAR for ruptured AAA is feasible in 40–60% of rupture cases and requires rapid CT angiography assessment. TEVAR requires adequate proximal and distal landing zones of 20 mm in non-aneurysmal aorta. Age is not a contraindication; endovascular approaches are often preferred in elderly or high-risk patients who cannot tolerate open surgery. Renal function must be assessed to plan contrast volume management; patients with eGFR below 30 may require CO2 angiography or intravascular ultrasound (IVUS)-guided deployment to minimize contrast nephropathy. Dual antiplatelet therapy (aspirin plus clopidogrel) is typically prescribed for 1–3 months after endovascular stenting procedures.

Endovascular procedures are performed in a hybrid operating theatre or angiography suite under local anaesthesia with sedation or general anaesthesia, using fluoroscopic X-ray guidance with iodinated contrast or carbon dioxide. Percutaneous transluminal angioplasty (PTA) uses a balloon catheter advanced over a guidewire across a stenosis or occlusion; balloon inflation dilates the vessel lumen and fractures the atheromatous plaque. Drug-coated balloons (DCB) impregnate the vessel wall with paclitaxel or sirolimus, reducing restenosis by inhibiting neointimal hyperplasia — particularly effective in superficial femoral artery and femoropopliteal disease. Bare-metal stents (BMS) and drug-eluting stents (DES) scaffold the vessel after angioplasty, preventing elastic recoil — nitinol self-expanding stents are preferred for the femoropopliteal segment; balloon-expandable stainless steel or chromium-cobalt stents for the aortoiliac, renal, and mesenteric segments. Covered stents (stent-grafts) line the vessel with expanded polytetrafluoroethylene (ePTFE) or Dacron, sealing aneurysms or fistulas. Endovascular aneurysm repair (EVAR, TEVAR for thoracic aorta, fEVAR for juxtarenal, bEVAR for thoracoabdominal) deploys bifurcated or tubular stent-grafts to exclude the aneurysm sac from systemic circulation. Mechanical thrombectomy using aspiration catheters (Penumbra Lightning, AngioJet) or rotational thrombectomy devices (Rotarex) rapidly removes acute arterial or venous thrombus. Transcatheter arteriovenous fistula creation (TAVI, WavelinQ) establishes dialysis access without surgical cutdowns. Visceral angioplasty and stenting treats mesenteric artery stenosis, renal artery fibromuscular dysplasia, and atherosclerotic renal artery stenosis.

Endovascular surgery offers dramatically reduced perioperative morbidity compared to open vascular surgery for most indications. EVAR perioperative mortality is 0.5–2% compared to 2–5% for open AAA repair (DREAM and EVAR-1 trials). Major 30-day morbidity is 5% for EVAR versus 15–20% for OSR. Blood loss is minimal with EVAR (typically under 500 mL) compared to 1,000–2,500 mL for OSR, virtually eliminating transfusion requirements. Hospital stay is 1–3 days after EVAR versus 7–10 days for open repair. ICU admission is rarely required after uncomplicated EVAR. Return to work and normal activities is possible within 1–2 weeks, compared to 6–8 weeks for open surgery. TEVAR for complicated type B dissection reduces 30-day mortality from 15–25% with medical management to 8–12% with endovascular repair. FEVAR and BEVAR at experienced centers achieve 30-day mortality of 2–5% for complex anatomy where open surgery carries 5–10% operative mortality. Long-term 10-year all-cause mortality is equivalent between EVAR and OSR (DREAM, EVAR-1, OVER trials), confirming EVAR's durability over the medium term despite the need for reinterventions.

Endoleak is the hallmark EVAR-specific complication, defined as persistent blood flow outside the stent-graft but within the aneurysm sac. Type I endoleak (proximal or distal seal failure) occurs in 2–5% and requires urgent reintervention (balloon dilation, relining, or open conversion) because it maintains aneurysm pressurization with rupture risk. Type II endoleak (retrograde flow from patent lumbar arteries or the inferior mesenteric artery) is the most common, occurring in 15–25% of EVAR cases; the majority are benign and spontaneously resolve, but those associated with sac expansion (over 5 mm growth) require intervention by embolization or EVAR relining. Type III endoleak from graft component separation requires reintervention. Device migration occurs in 2–5% of cases at 5 years. Stent-graft limb occlusion affects 1–3% and requires surgical or endovascular revision. Renal injury from contrast media is managed by hydration and contrast volume minimization. Post-implantation syndrome—self-limiting fever, leukocytosis, and elevated CRP in the first 2 weeks—occurs in 30–50% and does not indicate infection. Stent-graft infection is rare (0.2%) but life-threatening. Lifelong annual CT angiography surveillance is mandatory to detect endoleak, device migration, and sac growth; this represents a long-term commitment and cost burden compared to open repair, which requires no aneurysm-specific follow-up after successful graft exclusion.

Post-procedure monitoring begins with access site assessment: haematoma, pseudoaneurysm, and arterial-venous fistula at the femoral puncture site are the most common complications (combined 2–5%), monitored with duplex ultrasound if a pulsatile groin mass or bruit develops. Dual antiplatelet therapy (aspirin plus clopidogrel for 1–12 months depending on stent type and location) or single antiplatelet therapy is prescribed per procedural protocol. Anticoagulation with LMWH or unfractionated heparin is maintained for specific indications. Imaging surveillance post-EVAR follows CT angiography protocol as above. Post-tibial angioplasty for critical limb-threatening ischaemia, wound healing progress and haemodynamic improvement are assessed at 4–6 weeks using ABI, transcutaneous oxygen tension, and wound photography. For aortoiliac and femoropopliteal stents, duplex surveillance at 1 month, 6 months, and annually detects in-stent restenosis (greater than 50% narrowing) requiring reintervention. Six-minute walk test and ankle-brachial index document functional improvement in peripheral artery disease. For renal artery stenting, renal function (creatinine, eGFR) and blood pressure response are monitored at 1 month and 3 months. For visceral artery angioplasty (mesenteric artery stenosis), symptom resolution and weight recovery assess clinical response.

Endovascular surgery costs are driven substantially by device costs; a standard bifurcated EVAR stent-graft device alone costs USD 10,000–20,000 and a fenestrated EVAR device USD 30,000–50,000. In India, EVAR is available at JCI-accredited centers including Apollo Hospitals, Medanta, and Fortis with total procedure costs of USD 12,000–28,000, representing 60–70% savings versus US prices. India has highly trained vascular and interventional teams with modern hybrid operating theaters. Thailand offers EVAR at USD 18,000–40,000 at Bumrungrad International and Bangkok Dusit Medical Services. Turkey provides EVAR at USD 12,000–28,000 in Istanbul and Ankara centers. Germany charges EUR 25,000–60,000 at university hospitals for standard EVAR. In the United States, EVAR costs USD 35,000–85,000 as an all-inclusive hospital bill, with higher costs for fenestrated or branched procedures (USD 80,000–150,000). The UK performs EVAR on the NHS without patient cost for eligible residents. Singapore prices EVAR at USD 28,000–60,000. Australia charges AUD 35,000–75,000 (USD 25,000–55,000). Patients must also budget for annual CT surveillance (USD 500–1,500 per scan) and potential reinterventions, which occur in 10–15% of EVAR patients within 5 years.

Open surgical bypass is the established alternative to endovascular revascularisation for peripheral artery disease and remains superior in terms of durability for long-segment femoropopliteal occlusions exceeding 25 cm and aortoiliac occlusive disease (TASC II C and D lesions). Autologous great saphenous vein bypass grafts provide 5-year patency of 60–75% for femoropopliteal disease versus 40–60% for endovascular procedures in complex lesions. For infrapopliteal (tibial) disease, reversed saphenous vein bypass to the dorsalis pedis or posterior tibial artery remains effective for limb salvage in critical limb-threatening ischaemia. Medical therapy — optimal antiplatelet therapy (aspirin plus clopidogrel, or aspirin plus rivaroxaban 2.5 mg at COMPASS low-dose), high-intensity statin, smoking cessation, exercise rehabilitation — slows PAD progression and reduces major adverse cardiovascular events (MACE) and major adverse limb events (MALE). Supervised exercise therapy (structured treadmill programme) improves claudication distance by 150–200% in claudicants — equivalent to endovascular revascularisation in functional outcomes for intermittent claudication (CLEVER and ERASE trials). Hybrid procedures combine open endarterectomy or bypass with endovascular stenting, addressing multi-level disease in a single setting. Surgical profundoplasty (deep femoral artery endarterectomy and patch angioplasty) restores collateral outflow in patients with occluded superficial femoral arteries.